HAL Q2 | #2QWithCNBCTV18

Net #profit up 38.3% at Rs 848.2 Cr Vs Rs 613.4 Cr (YoY)

#Revenue up 14.4% at Rs 5,551.2 Cr Vs Rs 4,854 Cr (YoY)

#EBITDA up 20.8% at Rs 1,242 Cr Vs Rs 1,028 cr (YoY)

EBITDA #margin at 22.4% Vs 21.2% (YoY)

Working towards launch of new products to ensure growth going forward. Our #EBITDA margin will be in the range of 25-27%, says Ramesh Juneja of Mankind Pharma

Will reach #EBITDA breakeven of Apollo 24/7 by #Q4FY24. Apollo 24/7 will be #EBITDA neutral. #FY24 topline growth seen at 15%. Expect margin to be in the range of 15-16% by the end of FY24, says Suneeta Reddy of Apollo Hospitals

Expect #EBITDA to continue to improve from these levels. Expect #FY24 #margin of 13%. Expect FY24 #revenue growth of 15%, #growth will be volume led, says Kulin Lalbhai of Arvind Fashions

#PCBL reports #Q1 results

⭕️ Net #profit down 13.5% at ₹109.2 cr vs ₹126 cr (YoY)

⭕️ #Revenue down 4.4% at ₹1,347.5 cr vs ₹1,409 cr (YoY)

⭕️ #EBITDA up 7.9% at ₹210.7 cr vs ₹195.35 cr (YoY)

⭕️ #Margin at 15.6% vs 13.9% (YoY)

Operating #EBITDA margin will be in the range of 25-27% in next 2 years. We are looking at opportunities for inorganic #growth, says Nikhil Chopra of JB Chemicals & Pharma

#OnCNBCTV18 | FY24 #EBITDA margin will be over 14% & have a planned #capex of Rs 750 crore in this fiscal. Expect #growth of over 20-25% in plastic pipes, says MP Taparia of Supreme Industries https://t.co/iAVwc96j82

#OnCNBCTV18 | Will #maintain the guidance that we have given earlier. First time, retail business has shown positive #EBITDA. Maintain net debt to come down to ₹1,000 cr by #FY24, says Dipali Goenka of Welspun India

#1QWithCNBCTV18 https://t.co/SZjgAplMKr

#OnCNBCTV18 | #Q1 is a seasonally muted quarter. Occupancy is at 50%, #EBITDA jump is higher as all operating parameters have gained, says Ramesh Kancharla of Rainbow Children’s Medicare

Here's more
#1QWithCNBCTV18 https://t.co/F15b1SCZVT

Expect consolidated #EBITDA to increase from current levels of 16%. For standalone #business, demand #environment is benign across sectors and geographies, says Baba Kalyani of Bharat Forge https://t.co/NH5stCBhmm

#OnCNBCTV18 | Patel Group will increase stake by 1% in October, waiting for regulatory approval. Will try and increase our stake further if there are opportunities in future. On track to #achieve ₹630 cr #EBITDA by #FY25 & 18-20% topline #growth by FY25, says Tarak Patel of GMM… https://t.co/lIta75ttq4 https://t.co/FtQI3ChsAL

#EBITDA margin likely to sustain at current levels. Will consider to increase offerings in the #Palmolive range. Expect 2x growth in Palmolive vs overall portfolio, says Prabha Narasimhan of #Colgate to CNBC-TV18 https://t.co/vgZ6M5diTK